Due to rising rates of resistance, policy and opinion leaders have called for the development of entirely new paradigms of antimicrobial therapy to complement traditional antibiotics. Here we propose an innovative adjunctive antimicrobial approach to both prevent emergence of resistance in lethal pathogens and potentially treat XDR/PDR pathogens. We have found that recombinant human transferrin (rhTransferrin) effectively sequestered iron from Acinetobacter baumannii, methicillin resistant Staphylococcus aureus (MRSA), and Candida albicans, inhibiting their growth. Treatment with rhTransferrin improved survival of mice infected with lethal inocula of all three pathogens. Furthermore, adjunctive rhTransferrin therapy markedly reduced emergence of rifampin-resistance during treatment of mice with MRSA bacteremia. Finally, most recently, we found in vitro synergy between rhTransferrin and ciprofloxacin (cipro) against cipro-resistant K. pneumoniae. We will test the generalizability of these findings against Klebsiella pneumoniae and A. baumannii. Our novel strategy is to treat infection and inhibit emergence of resistance by rendering the host environment inhospitable to microbial growth. We will optimize this strategy as adjunctive therapy for infections in 3 AIMS:
AIM 1 : Determine the in vitro effects of adjunctive rhTransferrin on susceptibility and emergence of resistance to key antibacterial agents used to treat highly resistant Gram negative pathogens. The impact of rhTransferrin on in vitro susceptibility and resistance emergence to ciprofloxacin or meropenem will be defined for a panel of genetically well-characterized K. pneumoniae and A. baumannii strains. Trace metals and heme will be added back to determine if they reverse transferrin-mediated effects. In vitro time kill assays wil be used to determine how rhTransferrin alters the kinetics of antibacterial killing of the microbes AIM 2: Define optimal pharmacokinetics and pharmacodynamics of antibacterial agents with versus without adjunctive rhTransferrin. A sophisticated chemostat system will define dosing to optimize pharmacokinetic-pharmacodynamic (PK-PD) impact of rhTransferrin and antibiotic-transferrin combination therapy on cidality and emergence of antibiotic resistance of K. pneumoniae and A. baumannii. PD will be evaluated by measuring rhTransferrin-mediated metal sequestration and its impact on microbes.
AIM 3 : Define the in vivo efficacy and prevention of resistance of adjunctive rhTransferrin therapy.
Aims 1 and 2 will inform dosing strategies to define efficacy of adjunctive rhTransferrin plus antibiotics vs. antibiotic alone in mice infected iv or via the lung with K. pneumoniae or A. baumannii. Some groups will be treated with trace metals or heme to determine if efficacy is reversed. IMPACT: rhTransferrin already has been studied in clinical trials of patients with iron overload. Completion of the proposed studies will enable rapid clinical translation of rhTransferrin as adjunctive therapy to prevent the emergence of antibacterial resistance among pathogens with a high propensity to develop resistance.

Public Health Relevance

Policy and opinion leaders have called for the development of entirely new paradigms of antimicrobial therapy that have less potential to create new resistance compared to traditional antibiotics. We have discovered that a normal human protein, transferrin, has remarkably broad ability to inhibit the growth of microbes by passively starving them of the iron that they must steal from the host's body in order to grow. The purpose of this application is to optimize the strategy of administering supra-physiological doses of transferrin for life- threatening infections caused by pathogens with high propensity to cause resistance.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI117211-04
Application #
9640386
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Ernst, Nancy L
Project Start
2016-03-07
Project End
2021-02-28
Budget Start
2019-03-01
Budget End
2021-02-28
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Wald-Dickler, Noah; Holtom, Paul; Spellberg, Brad (2018) Busting the Myth of ""Static vs Cidal"": A Systemic Literature Review. Clin Infect Dis 66:1470-1474
Nielsen, Travis B; Yan, Jun; Luna, Brian et al. (2018) Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia. J Vis Exp :
Nielsen, Travis B; Pantapalangkoor, Paul; Luna, Brian M et al. (2017) Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis. J Infect Dis 216:489-501
Shin, Woo Shik; Bergstrom, Alexander; Bonomo, Robert A et al. (2017) Discovery of 1-Hydroxypyridine-2(1H)-thione-6-carboxylic Acid as a First-in-Class Low-Cytotoxic Nanomolar Metallo ?-Lactamase Inhibitor. ChemMedChem 12:845-849
Wong, Darren; Nielsen, Travis B; Bonomo, Robert A et al. (2017) Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin Microbiol Rev 30:409-447
Barnes, Melissa D; Winkler, Marisa L; Taracila, Magdalena A et al. (2017) Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from ?-Lactamase Protein Engineering. MBio 8:
Nielsen, Travis B; Pantapalangkoor, Paul; Yan, Jun et al. (2017) Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE. MBio 8:
Wong, Darren; Spellberg, Brad (2017) Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant Enterobacteriaceae. Virulence 8:383-390
Luna, Brian M; Ulhaq, Amber; Yan, Jun et al. (2017) Selectable Markers for Use in Genetic Manipulation of Extensively Drug-Resistant (XDR) Acinetobacter baumannii HUMC1. mSphere 2:
Marshall, Steven; Hujer, Andrea M; Rojas, Laura J et al. (2017) Can Ceftazidime-Avibactam and Aztreonam Overcome ?-Lactam Resistance Conferred by Metallo-?-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother 61:

Showing the most recent 10 out of 19 publications